Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma

Overview of attention for article published in Journal of Gastroenterology, October 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

policy: 2 policy sources
twitter: 1 X user

patent: 8 patents
facebook: 1 Facebook page

Citations

dimensions_citation: 291 Dimensions

Readers on

mendeley: 165 Mendeley

Summary Policy documents X Patents Facebook Dimensions citations

So far, Altmetric has seen 2 policy documents that reference this research output.

Lenvima for Hepatocellular Carcinoma – Details

Cited by Canadian Agency for Drugs and Technologies in Health on 01 Jun 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Lenvatinib for untreated advanced hepatocellular carcinoma : Appraisal consultation committee papers

Cited by National Institute for Health and Care Excellence on 01 Aug 2018

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.